vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and Sound Financial Bancorp, Inc. (SFBC). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $9.5M, roughly 1.3× Sound Financial Bancorp, Inc.). On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 1.5%). Sound Financial Bancorp, Inc. produced more free cash flow last quarter ($7.0M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 5.5%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

RNA vs SFBC — Head-to-Head

Bigger by revenue
RNA
RNA
1.3× larger
RNA
$12.5M
$9.5M
SFBC
Growing faster (revenue YoY)
RNA
RNA
+432.5% gap
RNA
434.0%
1.5%
SFBC
More free cash flow
SFBC
SFBC
$163.9M more FCF
SFBC
$7.0M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
5.5%
SFBC

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
RNA
RNA
SFBC
SFBC
Revenue
$12.5M
$9.5M
Net Profit
$-174.4M
Gross Margin
Operating Margin
-1513.5%
27.1%
Net Margin
-1398.3%
Revenue YoY
434.0%
1.5%
Net Profit YoY
-117.0%
EPS (diluted)
$-1.27
$0.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
SFBC
SFBC
Q4 25
$9.5M
Q3 25
$12.5M
$9.8M
Q2 25
$3.8M
$10.4M
Q1 25
$1.6M
$9.2M
Q4 24
$3.0M
$9.4M
Q3 24
$2.3M
$9.1M
Q2 24
$2.0M
$8.6M
Q1 24
$3.5M
$8.6M
Net Profit
RNA
RNA
SFBC
SFBC
Q4 25
Q3 25
$-174.4M
$1.7M
Q2 25
$-157.3M
$2.1M
Q1 25
$-115.8M
$1.2M
Q4 24
$-102.3M
Q3 24
$-80.4M
$1.2M
Q2 24
$-70.8M
$795.0K
Q1 24
$-68.9M
$770.0K
Operating Margin
RNA
RNA
SFBC
SFBC
Q4 25
27.1%
Q3 25
-1513.5%
21.3%
Q2 25
-4448.7%
24.5%
Q1 25
-8360.9%
15.9%
Q4 24
-4069.6%
24.6%
Q3 24
-4200.9%
15.6%
Q2 24
-4040.4%
11.4%
Q1 24
-2178.6%
10.9%
Net Margin
RNA
RNA
SFBC
SFBC
Q4 25
Q3 25
-1398.3%
17.3%
Q2 25
-4089.3%
19.8%
Q1 25
-7360.0%
12.7%
Q4 24
-3439.5%
Q3 24
-3441.7%
12.7%
Q2 24
-3461.8%
9.2%
Q1 24
-1943.4%
9.0%
EPS (diluted)
RNA
RNA
SFBC
SFBC
Q4 25
$0.87
Q3 25
$-1.27
$0.66
Q2 25
$-1.21
$0.79
Q1 25
$-0.90
$0.45
Q4 24
$-0.80
$0.74
Q3 24
$-0.65
$0.45
Q2 24
$-0.65
$0.31
Q1 24
$-0.79
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
SFBC
SFBC
Cash + ST InvestmentsLiquidity on hand
$350.2M
$138.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$109.4M
Total Assets
$2.1B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
SFBC
SFBC
Q4 25
$138.5M
Q3 25
$350.2M
$101.2M
Q2 25
$243.9M
$102.5M
Q1 25
$254.2M
$131.5M
Q4 24
$219.9M
$43.6M
Q3 24
$370.2M
$148.9M
Q2 24
$575.8M
$135.1M
Q1 24
$471.4M
$138.0M
Stockholders' Equity
RNA
RNA
SFBC
SFBC
Q4 25
$109.4M
Q3 25
$1.9B
$107.5M
Q2 25
$1.2B
$106.0M
Q1 25
$1.3B
$104.4M
Q4 24
$1.4B
$103.7M
Q3 24
$1.5B
$102.2M
Q2 24
$1.2B
$101.3M
Q1 24
$830.9M
$101.0M
Total Assets
RNA
RNA
SFBC
SFBC
Q4 25
$1.1B
Q3 25
$2.1B
$1.1B
Q2 25
$1.4B
$1.1B
Q1 25
$1.5B
$1.1B
Q4 24
$1.6B
$993.6M
Q3 24
$1.6B
$1.1B
Q2 24
$1.3B
$1.1B
Q1 24
$951.5M
$1.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
SFBC
SFBC
Operating Cash FlowLast quarter
$-156.2M
$7.2M
Free Cash FlowOCF − Capex
$-156.9M
$7.0M
FCF MarginFCF / Revenue
-1257.6%
73.4%
Capex IntensityCapex / Revenue
5.7%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M
$12.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
SFBC
SFBC
Q4 25
$7.2M
Q3 25
$-156.2M
$3.8M
Q2 25
$-199.7M
$-494.0K
Q1 25
$-124.8M
$1.9M
Q4 24
$-99.9M
$2.9M
Q3 24
$-65.6M
$3.3M
Q2 24
$-65.0M
$-4.0M
Q1 24
$-70.4M
$3.5M
Free Cash Flow
RNA
RNA
SFBC
SFBC
Q4 25
$7.0M
Q3 25
$-156.9M
$3.8M
Q2 25
$-203.0M
$-518.0K
Q1 25
$-128.6M
$1.8M
Q4 24
$-103.8M
$2.9M
Q3 24
$-67.3M
$3.2M
Q2 24
$-65.5M
$-5.6M
Q1 24
$-71.3M
$1.9M
FCF Margin
RNA
RNA
SFBC
SFBC
Q4 25
73.4%
Q3 25
-1257.6%
38.3%
Q2 25
-5277.1%
-5.0%
Q1 25
-8174.3%
19.8%
Q4 24
-3491.0%
30.4%
Q3 24
-2881.8%
35.5%
Q2 24
-3204.6%
-65.4%
Q1 24
-2012.3%
22.2%
Capex Intensity
RNA
RNA
SFBC
SFBC
Q4 25
1.8%
Q3 25
5.7%
0.4%
Q2 25
86.9%
0.2%
Q1 25
238.6%
0.4%
Q4 24
131.7%
0.8%
Q3 24
72.9%
0.5%
Q2 24
26.0%
18.7%
Q1 24
25.8%
19.0%
Cash Conversion
RNA
RNA
SFBC
SFBC
Q4 25
Q3 25
2.24×
Q2 25
-0.24×
Q1 25
1.59×
Q4 24
Q3 24
2.84×
Q2 24
-5.05×
Q1 24
4.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons